Crescent Grove Advisors LLC purchased a new stake in Merck & Company, Inc. (NYSE:MRK) in the second quarter, according to its most recent filing with the SEC. The fund purchased 16,909 shares of the company’s stock, valued at approximately $1,092,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of MRK. Guinness Asset Management Ltd grew its stake in Merck & by 13.3% during the 1st quarter. Guinness Asset Management Ltd now owns 154,380 shares of the company’s stock worth $9,809,000 after buying an additional 18,170 shares during the last quarter. Waldron LP grew its stake in Merck & by 54.3% during the 1st quarter. Waldron LP now owns 17,248 shares of the company’s stock worth $1,087,000 after buying an additional 6,071 shares during the last quarter. Personal Capital Advisors Corp grew its stake in Merck & by 9.3% during the 1st quarter. Personal Capital Advisors Corp now owns 86,154 shares of the company’s stock worth $5,483,000 after buying an additional 7,310 shares during the last quarter. BTIM Corp. grew its stake in Merck & by 3.3% during the 1st quarter. BTIM Corp. now owns 595,690 shares of the company’s stock worth $37,851,000 after buying an additional 18,967 shares during the last quarter. Finally, First Manhattan Co. grew its stake in Merck & by 2.6% during the 1st quarter. First Manhattan Co. now owns 243,433 shares of the company’s stock worth $15,192,000 after buying an additional 6,166 shares during the last quarter. Institutional investors and hedge funds own 72.84% of the company’s stock.
In other Merck & news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.25% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/11/16909-shares-in-merck-company-inc-mrk-purchased-by-crescent-grove-advisors-llc.html.
Shares of Merck & Company, Inc. (NYSE:MRK) traded down $0.73 during trading on Friday, reaching $55.48. The company had a trading volume of 16,743,801 shares, compared to its average volume of 9,494,131. The stock has a market cap of $153,140.61, a P/E ratio of 14.45, a P/E/G ratio of 2.42 and a beta of 0.78. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.21 and a current ratio of 1.43. Merck & Company, Inc. has a 1 year low of $54.41 and a 1 year high of $66.80.
Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The firm had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. During the same period in the prior year, the business earned $1.07 EPS. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. research analysts forecast that Merck & Company, Inc. will post 3.95 earnings per share for the current year.
A number of brokerages recently commented on MRK. Zacks Investment Research downgraded Merck & from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. BMO Capital Markets reissued a “buy” rating and issued a $72.00 price target on shares of Merck & in a research note on Friday, September 8th. UBS AG increased their price target on Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies set a $70.00 price target on Merck & and gave the stock a “buy” rating in a research note on Saturday, July 29th. Finally, BidaskClub raised Merck & from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $67.07.
Merck & Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.